Grace Therapeutics, Inc. (GRCE) faced a significant setback as the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for GTx-104, aimed at treating aneurysmal Subarachnoid Hemorrhage (aSAH). The CRL highlighted deficiencies in chemistry, manufacturing, and controls (CMC), as well as non-clinical toxicology assessments, which the company plans to address in a resubmission. Despite this, data from the Phase 3 STRIVE-ON trial indicated that GTx-104 could offer clinical benefits over oral Nimodipine, including reduced hypotension incidents and fewer ICU stays.
This development is critical for financial markets, as the CRL has led to a dramatic 45.48% drop in GRCE’s stock price, closing at $2.35, with further declines in after-hours trading. Investors will be closely monitoring the company’s next steps, including a planned Type A meeting with the FDA to clarify the resubmission process.
For market professionals, the key takeaway is the heightened volatility surrounding GRCE, underscoring the importance of regulatory approvals in biotech valuations and the potential for significant price movements in response to FDA communications.
Source: nasdaq.com